We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Efficacy and safety of glecaprevir and pibrentasvir in Japanese patients with hepatitis C virus infection aged 75 years or older.
- Authors
Komaki, Yuri; Ozono, Yoshinori; Nakamura, Kenichi; Iwakiri, Hisayoshi; Hasuike, Satoru; Sueta, Mitsue; Miike, Tadashi; Yamamoto, Shojiro; Uto, Hirofumi; Kusumoto, Kazunori; Ochiai, Toshimasa; Kato, Junya; Komada, Naoto; Kuroki, Kazuo; Eto, Toshiharu; Shigehira, Masafumi; Hirono, Shuichi; Nagata, Kenji; Kawakami, Hiroshi
- Abstract
<bold>Background: </bold>It is estimated that approximately 50% of patients with hepatitis C virus (HCV) infection in Japan are currently over 75 years old. However, patients aged ≥ 75 years are typically underrepresented in clinical trials of direct-acting antivirals. This study aimed to evaluate the efficacy and safety of glecaprevir and pibrentasvir (G/P) treatment in Japanese patients with HCV infection aged ≥ 75 years.<bold>Methods: </bold>This multicenter, retrospective study included 271 Japanese patients with HCV infection from 12 centers in Miyazaki Prefecture, Japan. Demographic, clinical, virological, and adverse events (AEs) data obtained during and after G/P treatment were collected from medical records. The patients were divided into two groups: younger (n = 199, aged < 75 years) and older (n = 72, aged ≥ 75 years). Virological data and AEs were analyzed according to the age group.<bold>Results: </bold>In intention-to-treat (ITT) and per-protocol analyses, the overall sustained virological response 12 (SVR12) rates were 93% and 98.8%, respectively. Two patients in the older group and 14 patients in the younger group dropped out before SVR12 assessment. Although patients in the older group tended to have liver cirrhosis, 95.8% in the older group and 92% in the younger group achieved SVR12 in the ITT analysis (P = 0.404). In total, 48 (17.7%) patients experienced treatment-related AEs. Common AEs during treatment included pruritus, headache, and fatigue. The AEs were not significantly different between the two groups.<bold>Conclusions: </bold>Compared with younger patients, older patients showed similar virological response and tolerance to G/P treatment.
- Subjects
JAPAN; HEPATITIS C; JAPANESE people; OLDER patients; HEPATITIS C virus
- Publication
BMC Gastroenterology, 2022, Vol 22, Issue 1, p1
- ISSN
1471-230X
- Publication type
journal article
- DOI
10.1186/s12876-022-02284-z